259 related articles for article (PubMed ID: 26994902)
1. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation.
Dodgshun AJ; SantaCruz N; Hwang J; Ramkissoon SH; Malkin H; Bergthold G; Manley P; Chi S; MacGregor D; Goumnerova L; Sullivan M; Ligon K; Beroukhim R; Herrington B; Kieran MW; Hansford JR; Bandopadhayay P
J Neurooncol; 2016 Jun; 128(2):293-302. PubMed ID: 26994902
[TBL] [Abstract][Full Text] [Related]
2. [BRAF V600E mutation and clinicopathologic characteristics in 250 cases of brain tumors associated with epilepsy].
Qi XL; Yao K; Duan ZJ; Bian Y; Ma Z; Piao YS; Gong LP
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):664-670. PubMed ID: 30220118
[No Abstract] [Full Text] [Related]
3. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.
Qaddoumi I; Orisme W; Wen J; Santiago T; Gupta K; Dalton JD; Tang B; Haupfear K; Punchihewa C; Easton J; Mulder H; Boggs K; Shao Y; Rusch M; Becksfort J; Gupta P; Wang S; Lee RP; Brat D; Peter Collins V; Dahiya S; George D; Konomos W; Kurian KM; McFadden K; Serafini LN; Nickols H; Perry A; Shurtleff S; Gajjar A; Boop FA; Klimo PD; Mardis ER; Wilson RK; Baker SJ; Zhang J; Wu G; Downing JR; Tatevossian RG; Ellison DW
Acta Neuropathol; 2016 Jun; 131(6):833-45. PubMed ID: 26810070
[TBL] [Abstract][Full Text] [Related]
5. Unusual high-grade features in pediatric diffuse leptomeningeal glioneuronal tumor: comparison with a typical low-grade example.
Schwetye KE; Kansagra AP; McEachern J; Schmidt RE; Gauvain K; Dahiya S
Hum Pathol; 2017 Dec; 70():105-112. PubMed ID: 28652147
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E mutation in epilepsy-associated glioneuronal tumors: Prevalence and correlation with clinical features in a Chinese population.
Zhang YX; Shen CH; Guo Y; Zheng Y; Zhu JM; Ding Y; Tang YL; Wang S; Ding MP
Seizure; 2017 Feb; 45():102-106. PubMed ID: 27984807
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors.
Prabowo AS; Iyer AM; Veersema TJ; Anink JJ; Schouten-van Meeteren AY; Spliet WG; van Rijen PC; Ferrier CH; Capper D; Thom M; Aronica E
Brain Pathol; 2014 Jan; 24(1):52-66. PubMed ID: 23941441
[TBL] [Abstract][Full Text] [Related]
9. Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.
Burger MC; Ronellenfitsch MW; Lorenz NI; Wagner M; Voss M; Capper D; Tzaridis T; Herrlinger U; Steinbach JP; Stoffels G; Langen KJ; Brandts C; Senft C; Harter PN; Bähr O
Oncol Rep; 2017 Dec; 38(6):3291-3296. PubMed ID: 29039591
[TBL] [Abstract][Full Text] [Related]
10. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants.
Lin A; Rodriguez FJ; Karajannis MA; Williams SC; Legault G; Zagzag D; Burger PC; Allen JC; Eberhart CG; Bar EE
J Neuropathol Exp Neurol; 2012 Jan; 71(1):66-72. PubMed ID: 22157620
[TBL] [Abstract][Full Text] [Related]
11. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours.
Nguyen AT; Colin C; Nanni-Metellus I; Padovani L; Maurage CA; Varlet P; Miquel C; Uro-Coste E; Godfraind C; Lechapt-Zalcman E; Labrousse F; Gauchotte G; Silva K; Jouvet A; Figarella-Branger D;
Neuropathol Appl Neurobiol; 2015 Apr; 41(3):403-8. PubMed ID: 25389051
[No Abstract] [Full Text] [Related]
12. A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology.
Hatae R; Hata N; Suzuki SO; Yoshimoto K; Kuga D; Murata H; Akagi Y; Sangatsuda Y; Iwaki T; Mizoguchi M; Iihara K
Neuropathology; 2017 Jun; 37(3):191-199. PubMed ID: 27792249
[TBL] [Abstract][Full Text] [Related]
13. Clinical responses of patients with diffuse leptomeningeal glioneuronal tumors to chemotherapy.
Aguilera D; Castellino RC; Janss A; Schniederjan M; McNall R; MacDonald T; Mazewski C
Childs Nerv Syst; 2018 Feb; 34(2):329-334. PubMed ID: 28965234
[TBL] [Abstract][Full Text] [Related]
14. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
[TBL] [Abstract][Full Text] [Related]
15. Diencephalic pediatric low-grade glioma harboring the BRAF V600E mutation presenting with various morphologies in sequential biopsy specimens.
Ishi Y; Hatanaka KC; Yamaguchi S; Fujita H; Motegi H; Kobayashi H; Terasaka S; Houkin K
Brain Tumor Pathol; 2017 Oct; 34(4):165-171. PubMed ID: 28836232
[TBL] [Abstract][Full Text] [Related]
16. Alterations in BRAF gene, and enhanced mTOR and MAPK signaling in dysembryoplastic neuroepithelial tumors (DNTs).
Kakkar A; Majumdar A; Kumar A; Tripathi M; Pathak P; Sharma MC; Suri V; Tandon V; Chandra SP; Sarkar C
Epilepsy Res; 2016 Nov; 127():141-151. PubMed ID: 27599148
[TBL] [Abstract][Full Text] [Related]
17. Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers.
Rankin A; Johnson A; Roos A; Kannan G; Knipstein J; Britt N; Rosenzweig M; Haberberger J; Pavlick D; Severson E; Vergilio JA; Squillace R; Erlich R; Sathyan P; Cramer S; Kram D; Ross J; Miller V; Reddy P; Alexander B; Ali SM; Ramkissoon S
Oncologist; 2021 Jan; 26(1):e153-e163. PubMed ID: 32918774
[TBL] [Abstract][Full Text] [Related]
18. Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.
Deng MY; Sill M; Chiang J; Schittenhelm J; Ebinger M; Schuhmann MU; Monoranu CM; Milde T; Wittmann A; Hartmann C; Sommer C; Paulus W; Gärtner J; Brück W; Rüdiger T; Leipold A; Jaunmuktane Z; Brandner S; Giangaspero F; Nozza P; Mora J; Morales la Madrid A; Cruz Martinez O; Hansford JR; Pietsch T; Tietze A; Hernáiz-Driever P; Stoler I; Capper D; Korshunov A; Ellison DW; von Deimling A; Pfister SM; Sahm F; Jones DTW
Acta Neuropathol; 2018 Aug; 136(2):239-253. PubMed ID: 29766299
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518
[TBL] [Abstract][Full Text] [Related]
20. H3K27-altered diffuse midline gliomas with MAPK pathway alterations: Prognostic and therapeutic implications.
Gestrich C; Grieco K; Lidov HG; Baird LC; Fehnel KP; Yeo KK; Meredith DM; Alexandrescu S
J Neuropathol Exp Neurol; 2023 Dec; 83(1):30-35. PubMed ID: 38037182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
